HD new abstract
39 clinical trials, 26 products, 1 drug, 6 abstracts
Abstract https://ir.ptcbio.com/static-files/b06f07d0-248f-404a-9041-2ec5aff2abceClinical trial:PTC518-CNS-002-HD,Indication:Huntington's disease,Product:Placebo,PTC518,Drug:PTC518,placebo, Search all connections |
Abstract https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-update-phase-iii-clinical-trials-amt-130-geneClinical trial:CT-AMT-130-01,Indication:Huntington's disease,Product:rAAV5-miHTT,Drug:AMT-130,Target:None, Search all connections |
Abstract https://ir.wavelifesciences.com/static-files/a3dbbb88-aebf-433d-8cb0-fcade9d43c23Clinical trial:WVE-003-001,Indication:Huntington's disease,Product:WVE-003,Placebo,Drug:WVE-003,placebo,Target:None, Search all connections |
Abstract https://www.nejm.org/doi/pdf/10.1056/NEJMc2300400Clinical trial:BN40423,Indication:Huntington's disease,Product:Tominersen,Placebo,Drug:tominersen,placebo,Target:None, Search all connections |
Clinical trial LY03015/CT-CHN-103A Randomized, Open-label, Two-period, Double-crossover Phase 1 Study to Evaluate the Effect of Food on the Pharmacokinetics of LPM3770164 Sustained-release Tablets in Healthy Subjects Organization:Luye Pharma Group,Product:LPM3770164,Indication:Tardive Dyskinesia,Huntington's disease, Search all connections |
Clinical trial MBF-015CT-02A Phase IIa, Open Label, Single Centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Orally Dosed MBF-015 in Huntington's Disease Patients |
Clinical trial 19_0081Study of Brain Derived Neurotrophic Factor (BDNF) Pathway Biomarkers in the Cerebrospinal Fluid in Patients With Huntington's Disease |
Clinical trial HUNTIAMMulticentric Trial on the Use of Combined Therapy of Thiamine and Biotine in Patients With Huntington´s Disease |
Clinical trial 20163022A Phase IIa, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Fenofibrate as a Treatment for Huntington's Disease Organization:University of Califo...,Product:Fenofibrate,Drug:Varlilumab,Indication:Huntington's disease, Search all connections |
Product Dextromethorphan + QuinidineIndication:Irritability,Amyotrophic lateral ...,Huntington's disease,Clinical trial:HSC-MS-18-1049,IRB201802938,Document:DailyMed Label: NUED...,DailyMed Label: Nued...,Organization:Avanir Pharmaceutica..., Search all connections |
Clinical trial HSC-MS-18-1049Evaluating the Efficacy of Dextromethorphan/Quinidine in Treating Irritability in Huntington's Disease Organization:The University of Te...,Product:Dextromethorphan + Q...,Indication:Irritability,Huntington's disease,Drug:Varlilumab, Search all connections |
Clinical trial 2015P000310Gait Pattern Analysis in Neurological Disease Organization:Beth Israel Deacones...,Product:Anti-Parkinson medic...,Indication:Parkinson's Disease,Atypical Parkinson's...,Progressive supranuc..., Search all connections |
Clinical trial CT-AMT-130-02A Phase Ib/II Randomized, Double-Blind Study to Explore Safety, Tolerability, and Efficacy Signals of Multiple Doses of Striatally-Administered rAAV5-miHTT Total Huntingtin Gene (HTT) Lowering Therapy (AMT 130) in Early Manifest Huntington's Disease |
Clinical trial 4443Risperidone for the Treatment of Huntington's Disease Chorea |
Clinical trial PTC518-CNS-004-HDA Phase 2b, Double-Blind, Randomized Extension Study to Evaluate the Long-Term Safety and Efficacy of PTC518 in Participants With Huntington's Disease |
Clinical trial APHP220809Evaluation of the Diagnostic Performance of Non-Invasive Prenatal Diagnosis for Single Gene Disorders Organization:Assistance Publique ...,Indication:Invasive Prenatal Di...,Inclusion,Sickle Cell Disease, Search all connections |
Clinical trial 200069Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease |
Product PridopidineIndication:Amyotrophic lateral ...,Huntington's disease,Clinical trial:PL101-HD301,PL101-ALS501,2019P003518D, Search all connections |
Clinical trial PL101-HD301A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Arm, Multicenter Study Evaluating the Efficacy and Safety of Pridopidine in Patients With Early Stage of Huntington Disease |
Clinical trial AVN011An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD) Organization:Azevan Pharmaceutica...,Product:Placebo,SRX246,Indication:Irritable Mood,Huntington's disease, Search all connections |
Clinical trial ASK-HD-01-CS-101An Open-Label Phase I/II Dose Finding Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Striatal Administration of AB-1001 in Adult Subjects With Early Manifest Huntington's Disease (HD) |
Clinical trial ACR16 C008A Multicentre, Multinational, Randomised, Double-Blind, Parallel-Group Study Comparing ACR16 45 mg Once-Daily or Twice-Daily Versus Placebo for the Symptomatic Treatment of Huntington's Disease |
Clinical trial BN40955An Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Intrathecally Administered RO7234292 (RG6042) in Patients With Huntington's Disease |
Clinical trial NBI-98854-HD3005A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease Product:Valbenazine,Placebo,Indication:Chorea,Huntington's disease,Organization:Neurocrine Bioscienc..., Search all connections |
Clinical trial ADORE-EXTClinical Extension Study for Assessing the Safety and Efficacy of the Intravenous Administration of Cellavita-HD in Huntington's Disease Patients Who Participated in the ADORE-DH Study. |
Clinical trial SAVE-DHFirst in Human Study to Evaluate Safety of Cellavita HD Investigational Product After Intravenous Application in Participants With Huntington's Disease |
Product SRX246Indication:Intermittent Explosi...,Irritable Mood,Huntington's disease,Clinical trial:AVN009,AVN011, Search all connections |
Clinical trial ER2001-001An Open-Label, Dose Escalation Early Phase 1 Study of ER2001 Intravenous Injection in Adults With Early Manifest Huntington's Disease |
Clinical trial ANX005-HD-01A Phase 2a Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ANX005 in Subjects With, or at Risk for, Manifest Huntington's Disease |
Product WVE-003Indication:Huntington's disease,Clinical trial:WVE-003-001,Abstract:Investigational Assa...,Genotyping single nu...,Impact of guanidine-..., Search all connections |
Clinical trial WVE-003-001A Multicenter, Randomized, Double-blind, Placebo Controlled, Phase 1b/2a Study of WVE-003 Administered Intrathecally in Patients With Huntington's Disease (SELECT-HD) Organization:Wave Life Sciences,Product:WVE-003,Indication:Huntington's disease,Abstract:https://ir.wavelifes..., Search all connections |
Clinical trial ACR16 C009A Multi-center, North American, Randomized, Double-blind, Parallel Group Study Comparing Three Doses of ACR16 Versus Placebo for the Symptomatic Treatment of Huntington Disease (HART) |
Clinical trial ADORE-DHDose-Response Evaluation of the Investigational Product Cellavita HD After Intravenous Administration in Patients With Huntington's Disease |
Clinical trial 718-CIH-301A Phase 3, Multicenter, Open-label Safety Study to Evaluate the Long-term Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease |
Product rAAV5-miHTTIndication:Huntington's disease,Clinical trial:CT-AMT-130-01,CT-AMT-130-02,Abstract:https://www.uniqure....,https://uniqure.gcs-..., Search all connections |
Product TominersenIndication:Huntington's disease,Clinical trial:BN42489,BN40423,BN40955,Abstract:Tominersen in Adults...,Targeting Huntingtin...,https://www.nejm.org..., Search all connections |
Clinical trial CT-AMT-130-01A Phase I/II, Randomized, Double-Blind, Sham Control Study to Explore Safety, Tolerability, and Efficacy Signals of Multiple Doses of Striatally-Administered rAAV5-miHTT Total Huntingtin Gene (HTT) Lowering Therapy (AMT-130) in Early Manifest Huntington's Disease Organization:uniQure Biopharma,Product:rAAV5-miHTT,Indication:Huntington's disease,Abstract:https://www.uniqure....,https://uniqure.gcs-..., Search all connections |
Clinical trial BN42489A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen in Individuals With Prodromal and Early Manifest Huntington's Disease |
Clinical trial STAR-0215-201A Phase 1b/2 Single and Multiple Dose Study to Assess the Safety, Tolerability, Clinical Activity, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of STAR-0215 in Participants With Hereditary Angioedema (The ALPHA-STAR Trial) Organization:Astria Therapeutics,Azidus Brasil,Product:STAR-0215,NestaCell®,Indication:Hereditary Angioedem...,Huntington's disease, Search all connections |
Product VO659Indication:Spinocerebellar Atax...,Spinocerebellar Atax...,Huntington's disease,Clinical trial:VO659-CT01, Search all connections |
Clinical trial VO659-CT01A Phase 1/2a, Open-label Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of Intrathecally Administered VO659 in Participants With Spinocerebellar Ataxia Types 1, 3 and Huntington's Disease Product:VO659,Indication:Spinocerebellar Atax...,Spinocerebellar Atax...,Huntington's disease,Organization:Vico Therapeutics, Search all connections |
Clinical trial LY03015/CT-CHN-102A Randomized, Double-blind, Placebo-controlled, Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetic of Multiple-ascending Doses of LPM3770164 Sustained-release Tablets in Healthy Subjects Organization:Luye Pharma Group,Product:LPM3770164,Indication:Tardive Dyskinesia,Huntington's disease, Search all connections |
Clinical trial 718-CIH-201A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease |
Product PTC518Indication:Huntington's disease,Clinical trial:PTC518-CNS-002-HD,PTC518-CNS-004-HD,Abstract:J06 Pivot-HD: a phas...,https://ir.ptcbio.co..., Search all connections |
Clinical trial PTC518-CNS-002-HDA Phase 2A, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of PTC518 in Subjects With Huntington's Disease Product:PTC518,Placebo,Organization:PTC Therapeutics,Indication:Huntington's disease,Abstract:https://ir.ptcbio.co..., Search all connections |
Clinical trial CLMI070C12203A Randomized, Double-Blind, Placebo-Controlled Dose Range Finding Study With Open-Label Extension to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of LMI070/Branaplam Administered as Weekly Oral Doses in Participants With Early Manifest Huntington's Disease |
Clinical trial BN40423A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington's Disease Organization:Hoffmann La Roche,Product:Placebo,Tominersen,Indication:Huntington's disease,Abstract:https://www.nejm.org..., Search all connections |
Product ANX005 |
Clinical trial NBI-98854-HD3006Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease |
Clinical trial NBI-98854-HD3022Open-Label Study of Valbenazine for the Treatment of Chorea Associated With Huntington Disease in Canada |
Product LPM3770164Indication:Tardive Dyskinesia,Huntington's disease,Clinical trial:LY03015/CT-CHN-101,LY03015/CT-CHN-102,LY03015/CT-CHN-103, Search all connections |
Clinical trial LY03015/CT-CHN-101A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 Sustained-release Tablets in Healthy Subjects Product:LPM3770164,Indication:Tardive Dyskinesia,Huntington's disease,Organization:Luye Pharma Group, Search all connections |
Product SAGE-718Indication:Huntington's disease,Parkinson's disease,Cognitive Impairment,Clinical trial:718-CIH-202, Search all connections |
Clinical trial 718-CIH-202A 28-Day Randomized, Placebo-Controlled, Double-Blind, Parallel Groups and Normative Comparison Study to Evaluate the Effect of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease |